LUOXIN AUROVITAS
GenericsLUOXIN AUROVITAS is a generic drug manufacturer focused on Respiratory.
LUOXIN AUROVITAS's Key Drugs
LUOXIN AUROVITAS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
LUOXIN AUROVITAS's Recent FDA Approvals
New NDA/BLA approvals for LUOXIN AUROVITAS over the last two years — novel drugs only, excluding generics and label supplements.
LUOXIN AUROVITAS's Therapeutic Areas
LUOXIN AUROVITAS's approved drugs and pipeline span 1 therapeutic area, led by Respiratory, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LUOXIN AUROVITAS's Top Competitors
LUOXIN AUROVITAS's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LUOXIN AUROVITAS Pipeline Snapshot
Active clinical trials for LUOXIN AUROVITAS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2016-10-27
- Latest
- 2023-07-21
- Applications
- 7